TREATMENT OF ACUTE NONLYMPHOCYTIC LEUKEMIA WITH ANTI-ANTIBODIES

用抗抗体治疗急性非淋巴细胞白血病

• 批准号: 3821094
• 负责人: FREDERICK APPELBAUM
• 金额: --
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3821094
• 关键词: antiidiotype antibody; autologous transplantation; bone marrow transplantation; cell differentiation; combination cancer therapy; cyclophosphamide; dogs; drug adverse effect; drug metabolism; hematopoiesis; human subject; human therapy evaluation; immunoconjugates; intravenous administration; lymphocytic leukemia; monoclonal antibody; myelogenous leukemia; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide therapy; nuclear medicine; radiation dosage; radionuclide imaging /scanning; radiopharmacology; remission /regression; whole body irradiation effect

The overall goal of project III is to evaluate the use of I-131- labeled anti-myeloid antibodies and autologous marrow transplantation as treatment for acute nonlymphocytic leukemia. This approach is based on the ability of labeled antibody to localize to the marrow space and the utility of external beam total body irradiation (TBI) with autologous marrow transplantation in treating ANL. We will initially measure the pharmacokinetics, biodistribution and associated radiation dosimetry of varying doses of I-131-labeled anti-myeloid antibodies in patients with ANL in second (or subsequent) remission. In patients in whom we achieve favorable dosimetry, we will evaluate the effects of increasing therapeutic doses of I- 131-labeled antibody with particular attention to the ability of the antibody-conjugate to ablate marrow, recovery of hematopoiesis following autologous transplantation, and the nature and extent of extramedullary toxicities. If favorable dosimetry is not achieved we will evaluate alternatives antibodies, forms of antibody (F(ab) or F(ab')2), or antibody infusion schedules.

项目三的总体目标是评估I-131的使用情况， 标记抗髓系抗体和自体骨髓 移植作为治疗急性非淋巴细胞白血病。 这种方法是基于标记抗体的能力， 定位于骨髓间隙和外部射线的应用 自体骨髓全身照射 移植治疗ANL。 我们最初将测量 药代动力学、生物分布和相关辐射 不同剂量的I-131标记的抗髓系 第二次（或随后）ANL患者的抗体 缓解。 在我们获得良好剂量测定的患者中， 我们将评估增加治疗剂量的I- 131-标记的抗体，特别注意 抗体-缀合物消融骨髓，恢复 自体移植后的造血，以及 髓外毒性的性质和程度。 如果有利 未达到剂量测定，我们将评估替代方案 抗体、抗体形式（F（ab）或F（ab '）2）或抗体 输注时间表。